[Anti-angiogenic strategy: therapy optimization of non-squamous non-small cell lung carcinoma]. / Antiangiogenes Wirkprinzip--Konzepte der Therapieoptimierung des nicht-squamösen nicht-kleinzelligen Lungenkarzinoms.
Pneumologie
; 68(12): 793-8, 2014 Dec.
Article
en De
| MEDLINE
| ID: mdl-25489867
Anti-angiogenic treatment with anti-VEGF compounds plays a central role in the therapy of non-squamous non-small cell lung cancer (NSCLC). However, biometric analysis of overall survival of the established treatment options reveals several limitations of efficacy in unselected patient cohorts. Furthermore, there are no established predictive biomarkers to help select patients who might benefit from this treatment option. This review focuses on underlying principles of action of tumor-related angiogenesis and presents new treatment options that may contribute to improved overall survival.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Inhibidores de la Angiogénesis
/
Neoplasias Pulmonares
/
Neovascularización Patológica
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
De
Revista:
Pneumologie
Año:
2014
Tipo del documento:
Article
Pais de publicación:
Alemania